Neuberger Berman Group’s Verona Pharma VRNA Stock Holding History

Neuberger Berman Group’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-337,445	Closed	-$36M	–	2201
2025 Q3	$36M	Buy	337,445 +259,300	+332%	+$27.1M	0.03%	535
2025 Q2	$7.39M	Sell	78,145 -4,380	-5%	-$324K	0.01%	859
2025 Q1	$5.24M	Sell	82,525 -70,819	-46%	-$4.24M	﹤0.01%	924
2024 Q4	$7.12M	Buy	153,344 +6,429	+4%	+$241K	0.01%	874
2024 Q3	$4.23M	Buy	146,915 +5,421	+4%	+$133K	﹤0.01%	979
2024 Q2	$2.05M	Sell	141,494 -72,737	-34%	-$1.06M	﹤0.01%	1092
2024 Q1	$3.45M	Buy	+214,231	New	+$3.7M	﹤0.01%	1014

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Neuberger Berman Group's VRNA Position: Q4 2025 in Review

Neuberger Berman Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 337,445 shares — an estimated $36M sold.

Neuberger Berman Group first reported a position in VRNA in Q1 2024 and held it in 7 quarters. The position peaked at $36M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Neuberger Berman Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Neuberger Berman Group sold 337,445 Verona Pharma shares in Q4 2025, an estimated $36M.
Neuberger Berman Group first reported a position in Verona Pharma in Q1 2024 and held it in 7 quarters.
Neuberger Berman Group's Verona Pharma position peaked at $36M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Neuberger Berman Group's 13F filing for Q4 2025, filed 13 Feb 2026.